| Literature DB >> 35910582 |
Cenyi Wang1, Jiling Liang2, Yuanyuan Ren1, Jielun Huang2, Baoming Jin1, Guodong Wang1, Ning Chen2.
Abstract
Background: Exercise is one of the most effective interventions for preventing and treating skeletal muscle aging. Exercise-induced autophagy is widely acknowledged to regulate skeletal muscle mass and delay skeletal muscle aging. However, the mechanisms underlying of the effect of different exercises on autophagy in aging skeletal muscle remain unclear.Entities:
Keywords: aging; autophagy; chronic exercise; skeletal muscle; systematic review
Year: 2022 PMID: 35910582 PMCID: PMC9329943 DOI: 10.3389/fphys.2022.930185
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.755
Inclusion and exclusion criteria. At each stage of the research analysis for inclusion review, papers were included and excluded according to the above criteria.
| Stage | Stage description | Inclusion criteria | Exclusion criteria |
|---|---|---|---|
| Ⅰ | Journal title analysis | Keywords: exercise, chronic exercise, physical activity, aging, skeletal muscle, autophagy, protein, gene | ① Keywords: human, younger age, review, myocardial, brain, liver cells, tissues (other than skeletal muscle); ② Languages other than English or Chinese; ③ Human model; ④ Aging animals and cell culture models (other than skeletal muscle); ⑤Review or methods paper; ⑥Abstract or full-test is unavailable; ⑦ Not original study; ⑧ Missing data; ⑨ Proteins or genes outside the range. |
| Ⅱ | Abstract analysis | ①Skeletal muscle tissue; ②Animal or cell model; ③Autophagy signaling activation; ④Chronic exercise. | |
| Ⅲ | Full text analysis | ①Skeletal muscle tissue; ②Animal or cell model; ③Autophagy signaling activation; ④Chronic exercise; ⑤Proteins include any one of the following: LC3, AMPK, Atg5/7/9/12, IGF-1, mTOR, FoxO3, Beclin1, Bcl-2, p62, PGC-1α. |
Note: LC3, microtubule-associated protein-1 lightchain 3; AMPK, adenosine monophosphate-activated protein kinase; Atg, autophagy-related; mTOR, mammalian target of rapamycin; IGF-1, Insulin-like Growth Factors 1; Bcl-2, B-cell lymphoma 2; PGC-1α, peroxisome proliferator-activated receptor γ coactivator1-α.
FIGURE 1Flow diagram of study selection process.
A summary of the reviewed articles.
| Study (author, year) | Research model | Location of skeletal muscles | Sample size | Age at start (months) | Exercise intervention | Outcome measures | Main findings of exercise in the intervention group | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Duration | Frequency | Intensity | Mode | |||||||
|
| Male Fischer 344 rats | Plantaris | EG:20 CG:19 | 3 | 84–85 weeks | Not reported | 1,145 ± 248 m/day | Lifelong VWR | Beclin-1, Atg7, Atg9, LC3-II/I ratio | No significant effects for Beclin-1; ↑Atg7 ( |
|
| Male Sprague Dawley rats | Gastrocnemius | EG:30 CG:8 | 18 | 8 weeks | 3 d/week | 0%, 30%, 50%, 70% maximum weight RE separately; speed:15 m/min, slope:35° | RE | Bcl-2 | ↑Bcl-2 (p <0.01 for 30% EG, p < 0.05 for 50% EG); No significant effects for Bcl-2 in 0% EG and 70% EG. |
|
| Male Sprague Dawley rats | Gastrocnemius | EG:19 CG:20 | 18-20 | 9 weeks | 3 d/week | 10 RM | RE | Beclin-1, Atg5-12, Atg7, LC3-II/ I ratio, p62, AMPK, IGF1, FoxO3a | ↑Beclin-1, Atg7, Atg5/12, AMPK, IGF1, FOXO3a ( |
|
| Male VCPR155H/+mice | Quadriceps | EG:8–10 CG:8–10 | 18 | 6 weeks | 3 d/week | 10–30 min (progressive) | TE | LC3-II/ I ratio, p62 | ↓LC3-II/ I ratio, p62 ( |
|
| Male C57BL/6 mice | Gastrocnemius | EG:15(TE=8, RE=7) CG:6 | 3 | 68 weeks | 3 d/week | TE:30 min/d; RE:2 Sets/d | Lifelong TE; RE | LC3-II/I ratio, Beclin1 | ↑LC3-II/I ratio (TE and RE, |
|
| Male C57BL/6 mice | Soleus | EG:20(LE=6, HE=7) CG:10 | 24 | 2 weeks | 5 d/week | 50 min/d, LE:8.8 m/min; HE:17.45 m/min | TE | Beclin-1, LC3-II/ I ratio, p62, PGC-1α | No significant effects for Beclin-1 and LC3-II/I ratio; ↑PGC-1α (2.2-fold higher in LE, 1.1-fold in HE, |
|
| Male wistar rats | Quadriceps | EG:6 CG:6 | 8 | 6 weeks | Not reported | 30-60 min/d, 60%VO2max | TE | mTOR, Bcl-2 | No significant effects for mTOR, Bcl-2. |
|
| Male andfemale C57BL/6J mice | Quadriceps | EG:13(M=6, F=7) CG:19(M=10, F=9) | 15 | 34 weeks | 4,5 d/week | 30 min/d | VWR (resistance) | LC3-II/ I ratio; p62 | No significant effects for p62; ↑LC3-II/ I ratio (elevated by 48% in M and 62% in F, |
|
| Male C57BL/6 mice | Gastrocnemius | EG:18(TE=9, RE=9) CG:9 | 17 | 16 weeks | 3 d/week | TE:40 min/d; RE:2 Sets /d | TE; RE | LC3-II/ I ratio, Beclin-1 | ↓Beclin1(TE and RE, |
|
| Male Wistar rats | Gastrocnemius + Soleus | EG:6 CG:6 | 20 | 12 weeks | 3 d/week | Progressive load of 65%–95% maximumcarrying capacity | RE | PGC-1α, IGF1, mTOR | ↑PGC-1α, IGF1, mTOR ( |
|
| Male Sprague Dawley rats | Soleus + Extensor digitorum longus | EG:8 CG:8 | 23–24 | 10 weeks | 5 d/week | 15-50 min (progressive), LE | TE | PGC-1α | ↑PGC-1α ( |
|
| Female C57BL/6 PGC-1α KO and WT mice (intercross breeding) | Quadriceps | EG:5-8 CG:5-8 | 3 | 48 weeks | Not reported | Not reported | Lifelong running wheel | LC3-II/ I ratio, LC3I, LC3II, Bcl-2, PGC-1α, p62 | No significant effects for LC3I, LC3II, Bcl-2, p62; ↑PGC-1α ( |
|
| Male wistar rats | Gastrocnemius | EG:40 CG:10 | 21 | 12 weeks | TE, RE, alternating ex (TE +RE): 3d/week; VWR: Free | TE: 4.2–12 m/min, 60 min(progressive); RE: 3 times/set, 2 sets /d; alternating ex (TE +RE): TE/RE protocols; VWR: Free | TE; RE; alternating ex (TE+ RE); VWR | Beclin-1, LC3-II/ I ratio, p62, mTOR, FOXO3a, Bcl-2, AMPK, PGC-1α | ↑Beclin-1( |
|
| Male ICR mice | Gastrocnemius | EG:10 CG:10 | 3 | 56 weeks | 5 d/week | 60 min | Lifelong TE | Beclin-1, LC3-II/LC3-I ratio, p62, mTOR, Bcl-2, AMPK, PGC-1α | ↑Beclin-1, LC3-II/ I ratio, AMPK ( |
|
| Male ICR mice | Gastrocnemius | EG:6 CG:6 | 3 | 57 weeks | 3 d/week | 3 times/set, 2 Sets/d | Lifelong RE | Beclin-1, Bcl-2 | ↑Beclin-1, Bcl-2( |
Note: KO, knock out; WT, wild type; M, male; F, female; LE. low intensity exercise; HE, high intensity exercise; VWR, voluntary wheel running; RE, resistance exercise training; TE, treadmill exercise; Ex, exercise; RM, repetition maximum.
Quality assessment of the included studies.
| Study (author, year) | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | (10) | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
|
| ✓ | ✓ | Nk | ✓ | ✓ | 4 | |||||
|
| ✓ | ✓ | ✓ | Nk | 3 | ||||||
|
| ✓ | ✓ | ✓ | Nk | ✓ | 4 | |||||
|
| ✓ | ✓ | ✓ | ✓ | 4 | ||||||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||
|
| ✓ | ✓ | ✓ | Nk | ✓ | 4 | |||||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||
|
| ✓ | ✓ | ✓ | ✓ | 4 | ||||||
|
| ✓ | ✓ | ✓ | Nk | ✓ | ✓ | ✓ | 6 | |||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | Nk | ✓ | ✓ | ✓ | 8 | |
|
| ✓ | ✓ | Nk | ✓ | ✓ | 4 |
Note: studies fulfilling the criteria of the following: (1), peer reviewed publication; (2), control of temperature; (3), random allocation to treatment or control; (4), blinded induction of model; (5), blinded assessment of outcome; (6), use of anesthetic without significant intrinsic neuroprotective activity; (7), appropriate animal model (aged, diabetic, or hypertensive); (8), sample size calculation; (9), compliance with animal welfare regulations; and (10), statement of potential conflict of interests. Nk, not known.
FIGURE 2The underlying mechanisms of exercise-induced autophagy in aging-induced skeletal muscle atrophy.